I was offline and couldn't watch the market last week so I went...

I was offline and couldn't watch the market last week so I went through my notes and came up with a few positives:

The rights issue is underwritten by 708 Equity, therefore funds for due diligence etc are guaranteed.

The new 5% shareholder is the manager of Trinity, the investment funder loaning Genome 300k for their end of Due Diligence and costs - so they obviously hold the project in good esteem to be investing as well as loaning.

DRK Directors have been keeping costs down - receiving shares in payments instead of cash - so with skin in the game they would be looking for a good deal to help them recover some funds for work done.

DRK have gold assets to sell and the gold price has seen increases lately, which could make selling easier/more profitable than when gold is bearish.

Consolidation could be a minimum of 1:10. Could be 2: or 5:10 or? depending on where the share price is to consolidate to 2c. Each point higher means less dilution. As management have skin in the game, the less dilution the better for them.

Genome - Professionalism - Genome had a major spelling typo on their website home page- when contacted they responded with gratitude and fixed it promptly.

Next few weeks:

Meeting - if DRK usurpers are successful, the deal will not go ahead, they need to be voted against. (Very little chance they would succeed anyway, with no plan and such a greeat opportunity to turn DRK around)
Tenement sale news. Possibility of a tenement sale bringing in extra cash.
Due Diligence - Due around 8th April - 4 weeks seems short for due diligence but the shorter the better.

Well done to those averaging down - I hope you are finally rewarded.

I didn't watch the market this week but the charts suggest the wall at .005 burst into .004 and now supply looks to be getting thin. Excellent!